Quattro Financial Advisors LLC Sells 19,600 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Quattro Financial Advisors LLC reduced its stake in Bristol Myers Squibb by 78.4%, selling 19,600 shares and holding only 5,400 shares worth $250,000 at the end of the last reporting period.
• Wall Street analysts have mixed ratings for Bristol Myers Squibb, with an average rating of "Hold" and a price target of $56.38, while recent earnings reports exceeded expectations.
• Bristol Myers Squibb announced a quarterly dividend of $0.62 per share, yielding 5.4%, set to be paid on November 3rd to investors of record as of October 3rd.

Quattro Financial Advisors LLC lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 78.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,400 shares of the biopharmaceutical company's stock after selling 19,600 shares during the period. Quattro Financial Advisors LLC's holdings in Bristol Myers Squibb were worth $250,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol Myers Squibb during the first quarter worth $31,000. Accent Capital Management LLC bought a new position in Bristol Myers Squibb during the first quarter worth $33,000. CBIZ Investment Advisory Services LLC raised its stake in Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 231 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Bristol Myers Squibb during the first quarter worth $36,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the first quarter worth $37,000. Institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price for the company. in a research note on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a "moderate buy" rating in a report on Thursday. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Stock Down 3.5%

Shares of NYSE BMY opened at $45.75 on Friday. The stock has a market capitalization of $93.12 billion, a P/E ratio of 18.45, a P/E/G ratio of 2.43 and a beta of 0.33. The company has a 50-day moving average price of $46.42 and a 200-day moving average price of $48.76. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the firm earned $2.07 earnings per share. The firm's revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 100.00%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.